{"nctId":"NCT04739306","briefTitle":"Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema","startDateStruct":{"date":"2021-07-22","type":"ACTUAL"},"conditions":["Diabetic Macular Edema (DME)"],"count":348,"armGroups":[{"label":"CT-P42","type":"EXPERIMENTAL","interventionNames":["Biological: CT-P42"]},{"label":"Eylea","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Eylea"]}],"interventions":[{"name":"CT-P42","otherNames":[]},{"name":"Eylea","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patient aged ≥18 years.\n* Patient with DME secondary to DM involving the center of the macula (defined as the Optical Coherence Tomography \\[OCT\\] central subfield) in the study eye.\n\nExclusion Criteria:\n\n* Patient who has only one functional eye.\n* Patient who currently has, or has a history (where indicated) of active proliferative diabetic retinopathy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 8","description":"Mean change from baseline in BCVA as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) letters at week 8.\n\nSubjects with a BCVA ETDRS letter score of 73 to 34 (= Acuity of 20/40 to 20/200) in the study eye at Screening and Day 1 were included. Visual acuity of the study eye was assessed using the ETDRS charts; a higher score represents better functioning.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.43","spread":"0.798"},{"groupId":"OG001","value":"8.85","spread":"0.775"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in BCVA at Week 52","description":"Mean change from baseline in BCVA as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) letters at week 52.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":"8.9"},{"groupId":"OG001","value":"11.1","spread":"9.9"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Who Gained ≥15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52","description":"Proportion of subjects who gained ≥15 letters from baseline in BCVA, assessed in change from baseline in ETDRS letters over time","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52","description":"The ETDRS DRSS score was grouped into 13 severity scores based on the ETDRS Severity Level.\n\nDR absent (level 10); Mild to moderate nonproliferative DR (levels 20, 35, and 43); Moderately severe/severe/Very Severe nonproliferative DR (levels 47, 53 and 53E); Inactive/Mild/moderate/high-risk/advanced proliferative DR (levels 60, 61, 65, 71,75, 81, and 85)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Central Subfield Thickness (CST) at Week 52 as Assessed on Optical Coherence Tomography (OCT)","description":"The mean change from baseline in Central Subfieldl Thickness as determined by Spectral domain- Optical coherence tomography (SD-OCT)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-220.7","spread":"147.1"},{"groupId":"OG001","value":"-191.2","spread":"137.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":174},"commonTop":["Diabetic retinal oedema","Hypertension","COVID-19","Diabetes mellitus inadequate control","Nasopharyngitis"]}}}